Autism Expert Center and Autism Resource Center of Limousin, University Hospital Center, Limoges, France.
Neurochlore, Luminy Scientific Campus, Marseille, France.
J Am Acad Child Adolesc Psychiatry. 2021 Aug;60(8):937-938. doi: 10.1016/j.jaac.2020.09.025. Epub 2020 Dec 29.
In their article in the Journal, Sprengers et al. conclude that bumetanide does not attenuate autism spectrum disorder (ASD) despite a nominally significant treatment effect in repetitive behaviors, which is a core symptom of ASD but was defined as a secondary measure in this trial. Four earlier studies performed by 3 independent institutes, including 2 studies not mentioned by Sprengers et al., testing a total of 169 children (versus 122 placebo) showed a significant amelioration of ASD symptoms. Bumetanide also significantly attenuated behavioral features of patients with tuberous sclerosis according to another study by Sprengers' same group..
在他们发表在《期刊》上的文章中，Sprengers 等人得出结论，布美他尼并没有减轻自闭症谱系障碍（ASD），尽管在重复行为方面有明显的治疗效果，这是 ASD 的核心症状，但在这项试验中被定义为次要措施。包括 Sprengers 等人未提及的两项研究在内的三个独立研究所进行的四项早期研究，共测试了 169 名儿童（与 122 名安慰剂组相比），结果显示 ASD 症状有显著改善。根据 Sprengers 同一团队的另一项研究，布美他尼还显著减轻了结节性硬化症患者的行为特征。
